10-Q: Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Palisade Bio's second quarter 2024 report highlights ongoing development of PALI-2108, recent financings, and a focus on cost management.

Summary

• Palisade Bio is a pre-clinical stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases.
• The company's lead product candidate, PALI-2108, is being developed as a therapeutic for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
• As of June 30, 2024, Palisade Bio had an accumulated deficit of $129.1 million and cash and cash equivalents of approximately $11.4 million.
• The company expects to continue to incur losses in the foreseeable future.
• A 1-for-15 reverse stock split was effected on April 5, 2024.
• In May 2024, the company completed a private placement for net cash proceeds of approximately $3.5 million.
• In February 2024, the company completed a warrant inducement transaction for net cash proceeds of approximately $2.2 million.
• The company believes it has sufficient cash to fund its currently planned operations through the first quarter of 2025.
• Research and development expenses for the three months ended June 30, 2024 were $2.6 million, compared to $2.2 million for the same period in 2023.
• General and administrative expenses for the three months ended June 30, 2024 were $1.6 million, compared to $1.4 million for the same period in 2023.
• Net loss for the three months ended June 30, 2024 was $4.1 million, compared to $3.4 million for the same period in 2023.
• The company has a corporate office lease with total remaining future minimum lease payments of approximately $163,000 as of June 30, 2024.

Sentiment

Score: 4

Explanation: The document highlights progress in drug development and recent financings, but the company's financial losses, going concern uncertainty, and material weakness in internal controls temper the overall sentiment.

Positives

• The company successfully completed a private placement and warrant inducement transaction, strengthening its financial position.
• The company is making progress in pre-clinical studies of PALI-2108, with plans to initiate clinical trials soon.
• The company has completed GMP manufacturing of PALI-2108 drug substance and engineering batches of the drug product.
• The company is developing a biomarker-based patient selection approach, which could improve clinical trial outcomes.
• The company has a strategic collaboration with Strand Life Sciences to identify biomarkers and develop optimal algorithms to aid in patient selection.

Negatives

• The company has a history of net operating losses and expects to continue to incur losses.
• The company has an accumulated deficit of $129.1 million.
• The company has expressed substantial doubt about its ability to continue as a going concern.
• The company's disclosure controls and procedures were not effective at a reasonable assurance level due to a material weakness in internal control over financial reporting.
• The company's research and development expenses increased by 21% for the three months ended June 30, 2024 compared to the same period in 2023.

Risks

• The company's business depends on the successful development and commercialization of PALI-2108, which is subject to substantial risks.
• The company may not be able to obtain regulatory approval for PALI-2108.
• The company depends on its license agreement with Giiant, and termination of this agreement could harm the business.
• The company will need to raise additional capital, which may not be available on favorable terms or at all.
• The company's common stock could be delisted from the Nasdaq Stock Market if it fails to maintain compliance with listing standards.
• The company relies on third-party contractors for manufacturing and clinical trials, which exposes it to risks.
• The company has a material weakness in internal controls over financial reporting, which could result in material misstatements in its financial statements.

Future Outlook

The company plans to submit an IND/CTA in the third quarter of 2024 and initiate clinical trials of PALI-2108 in the fourth quarter of 2024. Topline data from the Phase 1 SAD/MAD trial is expected late in the first half of 2025. Following the completion of the Phase 1 SAD/MAD trial, the company plans to initiate a Phase 1b/2a proof-of-concept trial in UC patients in the second half of 2025.

Management Comments

• The company believes it has sufficient cash to fund its currently planned operations through the first quarter of 2025.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. The development of PALI-2108 for inflammatory bowel disease aligns with the industry's focus on targeted therapies and precision medicine.

Comparison to Industry Standards

• The company's cash burn rate and operating losses are typical for a pre-clinical stage biopharmaceutical company.
• The company's focus on a biomarker-based patient selection approach is consistent with industry trends towards precision medicine.
• The company's reliance on third-party contractors for manufacturing and clinical trials is a common practice in the industry.
• The company's timeline for initiating clinical trials of PALI-2108 is consistent with the typical development timelines for similar drug candidates.
• The company's recent financings are similar to those of other companies in the sector, but the company's need for additional capital is a risk factor.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• Employees may be affected by potential cost-cutting measures or changes in operations.
• Customers (potential patients) may benefit from the development of new therapies.
• Suppliers and creditors may be affected by the company's financial condition and ability to pay.

Next Steps

• The company plans to submit an IND/CTA in the third quarter of 2024.
• The company plans to initiate clinical trials of PALI-2108 in the fourth quarter of 2024.
• The company plans to initiate a Phase 1b/2a proof-of-concept trial in UC patients in the second half of 2025.

Key Dates

Keywords

PALI-2108, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease, Biopharmaceutical, Clinical Trials, Pre-clinical Studies, Drug Development, Biomarkers, Reverse Stock Split, Warrant Inducement, Private Placement, GMP Manufacturing, Giiant Pharma, PDE4 Inhibitor